TERN
Terns Pharmaceuticals Inc

2,417
Mkt Cap
$5.15B
Volume
3,090.00
52W High
$50.00
52W Low
$1.87
PE Ratio
-46.94
TERN Fundamentals
Price
$48.44
Prev Close
$49.06
Open
$48.52
50D MA
$39.67
Beta
1.02
Avg. Volume
2M
EPS (Annual)
-$1.12
P/B
14.92
Rev/Employee
$0.00
$83.65
Loading...
Loading...
News
all
press releases
Terns Pharmaceuticals (NASDAQ:TERN) Lowered to "Sell" Rating by Wall Street Zen
Wall Street Zen cut Terns Pharmaceuticals from a "hold" rating to a "sell" rating in a research note on Saturday...
MarketBeat·2d ago
News Placeholder
More News
News Placeholder
Terns Pharmaceuticals (NASDAQ:TERN) Sets New 12-Month High - Should You Buy?
Terns Pharmaceuticals (NASDAQ:TERN) Hits New 52-Week High - What's Next...
MarketBeat·3d ago
News Placeholder
Amy Burroughs Sells 14,583 Shares of Terns Pharmaceuticals (NASDAQ:TERN) Stock
Terns Pharmaceuticals, Inc. (NASDAQ:TERN - Get Free Report) CEO Amy Burroughs sold 14,583 shares of the firm's stock in a transaction dated Monday, March 16th. The stock was sold at an average price...
MarketBeat·5d ago
News Placeholder
This Biotech Attracted a $181 Million Investment During a Staggering 1,300% Stock Rally
Key PointsVestal Point acquired 4,500,000 shares of Terns Pharmaceuticals in the fourth quarter...
Nasdaq News: Markets·6d ago
News Placeholder
Zacks Industry Outlook Highlights Terns Pharmaceuticals, ADMA Biologics, ANI Pharmaceuticals and Liquidia
Biotech momentum in 2026 spotlights companies like Liquidia and ANI Pharmaceuticals as pipeline innovation, drug demand and rising M&A activity drive sector interest.
Zacks·7d ago
News Placeholder
Terns Pharmaceuticals, Inc. (NASDAQ:TERN) Receives Consensus Recommendation of "Buy" from Analysts
Terns Pharmaceuticals, Inc. (NASDAQ:TERN - Get Free Report) has received an average recommendation of "Buy" from the fourteen analysts that are presently covering the firm, Marketbeat.com reports...
MarketBeat·7d ago
News Placeholder
5,700,000 Shares in Terns Pharmaceuticals, Inc. $TERN Acquired by Commodore Capital LP
Commodore Capital LP acquired a new position in Terns Pharmaceuticals, Inc. (NASDAQ:TERN - Free Report) during the third quarter, according to the company in its most recent Form 13F filing with the...
MarketBeat·8d ago
News Placeholder
4 Biotech Stocks to Watch for Potential Upside in 2026
New drug approvals and encouraging pipeline progress should maintain momentum in the Zacks Biomedical and Genetics industry despite the uncertain macroeconomic environment. A strong portfolio and solid pipeline progress position TERN, ADMA, ANIP and LQDA in this volatile sector.
Zacks·10d ago
News Placeholder
Terns Pharmaceuticals (NASDAQ:TERN) Trading 4.8% Higher - What's Next?
Terns Pharmaceuticals (NASDAQ:TERN) Shares Up 4.8% - Time to Buy...
MarketBeat·10d ago
News Placeholder
Terns Pharmaceuticals Sees Unusually Large Options Volume (NASDAQ:TERN)
Terns Pharmaceuticals, Inc. (NASDAQ:TERN - Get Free Report) saw unusually large options trading activity on Friday. Stock investors purchased 9,767 call options on the stock. This represents an...
MarketBeat·10d ago
<
1
2
...
>

Latest TERN News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.